POLR3H

Across TCGA pan-cancer cohorts, POLR3H Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated POLR3H data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher POLR3H Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated POLR3H expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

LUSC, LIHC, and STAD are the cancer types where POLR3H Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.011	0.762	<.001	30	view →
LIHC	DFS	Median	All	0.040	0.553	<.001	18	view →
STAD	DFS	Median	All	0.192	0.555	.026	15	view →
BLCA	DFS	Median	All	0.884	0.327	.029	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	II,III,IV	1.000	0.445	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

POLR3H–LUSC (OS)

Open the LUSC breakdown →